Ohm Laboratories gets FDA warning for manufacturing issues

12/27/2009 | Wall Street Journal, The

Ohm Laboratories, a unit of Indian drug firm Ranbaxy Laboratories, received a warning letter from the FDA regarding manufacturing violations at a Gloversville, N.Y., facility. Ranbaxy said the agency "did not observe any material deviation" in the unit's other facilities in the U.S. and that it plans to cooperate with the agency.

View Full Article in:

Wall Street Journal, The